Qiagen has patented a method to analyze biomarker RNA in circulating tumor cells and extracellular vesicles to enhance cancer patient management. The method combines expression profiles to provide diagnostic, prognostic, and predictive information, aiding in treatment decisions. GlobalData’s report on Qiagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Qiagen NV - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Qiagen, Nucleoside chemical synthesis was a key innovation area identified from patents. Qiagen's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Method for analyzing rna biomarkers to determine cancer treatment effectiveness

Source: United States Patent and Trademark Office (USPTO). Credit: Qiagen NV

The granted patent (Publication Number: US11840734B2) outlines a method for evaluating the effectiveness of anti-RANKL antibody therapy in cancer patients. The method involves isolating RNA from circulating tumor cells and extracellular vesicles, determining the expression of AURKA, and creating an expression profile. By identifying overexpression of AURKA, the method recommends ceasing anti-RANKL antibody therapy and switching to a different treatment for cancer management.

The patent further details variations of the method, including different approaches to obtaining biological samples, isolating circulating tumor cells, and determining AURKA expression through reverse transcription and quantitative polymerase chain reaction. The biological samples can include liquid biopsies from bodily fluids like blood and urine, with the goal of identifying AURKA overexpression as an indicator of resistance or failure to denosumab bone stabilization therapy. The specificity of the predetermined threshold value for AURKA expression is set at a minimum of 90% to ensure accurate assessment of therapy effectiveness. The method provides a comprehensive approach to personalized cancer treatment based on molecular markers like AURKA expression levels in circulating tumor cells and extracellular vesicles.

To know more about GlobalData’s detailed insights on Qiagen, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.